Review highlights promise of vincristine-ivermectin in CTVT

A new Veterinary Evidence review is putting fresh attention on an old question in canine oncology: does adding ivermectin to vincristine improve outcomes in dogs with canine transmissible venereal tumour, or CTVT? The review assessed randomized controlled evidence comparing vincristine alone with vincristine-ivermectin combination therapy, a topic that has drawn interest because vincristine is already the established first-line treatment, but resistance, treatment duration, and cumulative toxicity remain practical concerns in some cases. (pubmed.ncbi.nlm.nih.gov)

That context matters. A 2025 systematic review and meta-analysis covering CTVT treatment literature from 1950 to 2023 concluded that vincristine sulphate monotherapy remains the recommended first-line treatment. The same review noted the need for alternatives in vincristine-resistant disease, but did not elevate adjunct ivermectin to standard-of-care status. In other words, the baseline for clinicians has not changed: vincristine still anchors treatment, and any adjunct should be judged against a therapy that already performs well in most dogs. (pubmed.ncbi.nlm.nih.gov)

The most detailed recent evidence comes from a randomized, controlled, double-blinded study published in the Journal of Veterinary Internal Medicine in early 2026. Investigators enrolled 20 client-owned dogs with cytologically confirmed CTVT and randomized them to vincristine alone or vincristine plus ivermectin. Vincristine was given at 0.5 mg/m² IV weekly in both groups, while the combination group also received ivermectin at 0.5 mg/kg subcutaneously at diagnosis and again 24 hours later. Treatment continued until both gross and cytologic remission were confirmed. (academic.oup.com)

That study found a shorter treatment duration with the combination protocol. According to the abstract, aggressive tumours reached remission in 4.3 ± 0.3 weeks with vincristine-ivermectin versus 5.9 ± 0.2 weeks with vincristine alone. Non-aggressive tumours reached remission in 3.8 ± 0.2 weeks versus 5.5 ± 0.3 weeks, respectively. The authors reported no significant differences in red or white blood cell parameters, and concluded that the adjunct effect appeared strongest in aggressive CTVT. They also proposed a structured clinical-cytological scoring system to stratify tumour aggressiveness, which could become relevant if future studies confirm that not all CTVT cases benefit equally from combination treatment. (pubmed.ncbi.nlm.nih.gov)

At the same time, the paper is best read as hypothesis-strengthening rather than practice-settling. The investigators themselves described the trial as exploratory, with only five dogs per subgroup after stratification. They also noted that the small sample size limited statistical sensitivity and that the absence of cytotoxicity markers or histopathology constrained mechanistic conclusions. That caution lines up with the wider literature, where earlier prospective work also suggested benefit from vincristine-ivermectin combinations, but the overall evidence base remains thin and heterogeneous. (academic.oup.com)

Why it matters: For veterinary teams, the appeal of a faster remission protocol is straightforward. Fewer vincristine visits could reduce cumulative drug exposure, simplify scheduling, lower handling demands for stressed patients, and ease the treatment burden on pet parents. But there are also reasons to move carefully. Because vincristine monotherapy remains the evidence-backed first-line standard, clinicians considering adjunct ivermectin would need to weigh the modest dataset, case selection, local formulary practices, and breed-specific drug sensitivity concerns, particularly around MDR1-related risk discussions when ivermectin enters the plan. The current evidence is promising, but not yet strong enough to redefine standard protocol across general practice or referral oncology. (pubmed.ncbi.nlm.nih.gov)

There also appears to be growing research interest in refining which CTVT cases need more than standard vincristine. The 2026 JVIM study explicitly tied response to tumour aggressiveness, and newer observational and smaller clinical reports continue to explore combination approaches in difficult or atypical cases. If that line of work holds up, the real value of ivermectin may not be as a universal add-on, but as a targeted adjunct in dogs with more aggressive cytologic or clinical features. That is still an inference from early data, rather than a settled conclusion. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next milestone is larger, adequately powered controlled trials that test vincristine-ivermectin protocols across defined CTVT subtypes, confirm safety, and show whether shorter treatment duration translates into better real-world value for clinics and pet parents. (academic.oup.com)